Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SSX family member 19, pseudogene (SSX19P), also known as psiSSX9 or SSXP9, is classified as a pseudogene within the synovial sarcoma X breakpoint protein (SSX) family[3]. Unlike functional SSX family members (e.g., SSX1, SSX2), which are cancer-testis antigens implicated in tumor biology, SSX19P does not encode a functional protein and has no described biological activity or disease relevance[1][2][3]. It is carried as an annotation in genomics resources largely for reference and does not serve as a therapeutic target; no drug interactions or clinical biomarkers are associated with it.
None (as it is a pseudogene, not a drug target)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SSX family member 19, pseudogene (SSX19P).